Jenburkt Pharmaceuticals Limited Stock Price Today (NSE: JENBURPH)
Fundamental Score
Jenburkt Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Jenburkt Pharmaceuticals Limited share price today is ₹992.00, up +1.84% on NSE/BSE as of 16 September 2026. Jenburkt Pharmaceuticals Limited (JENBURPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹483.43 (Cr). The 52-week high for JENBURPH share price is ₹1073.90 and the 52-week low is ₹960.30. At a P/E ratio of 12.85x, JENBURPH is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 20.40% and a debt-to-equity ratio of 0.01.
Jenburkt Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Jenburkt Pharmaceuticals Limited share price chart: -5.75% return over the past month. 52-week high ₹1073.90, 52-week low ₹960.30.
Jenburkt Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹988.00 | ₹994.90 | ₹960.30 | ₹992.00 | 571.00 (Cr) | |
| ₹991.20 | ₹1018.30 | ₹971.00 | ₹974.10 | 4.11K (Cr) | |
| ₹1020.00 | ₹1034.80 | ₹998.60 | ₹1003.90 | 1.78K (Cr) | |
| ₹1026.60 | ₹1047.00 | ₹1000.00 | ₹1026.80 | 3.35K (Cr) | |
| ₹1052.50 | ₹1052.90 | ₹1021.20 | ₹1023.70 | 1.11K (Cr) | |
| ₹1052.00 | ₹1052.00 | ₹1025.10 | ₹1039.90 | 276.00 (Cr) | |
| ₹1022.20 | ₹1057.00 | ₹1022.20 | ₹1043.00 | 575.00 (Cr) | |
| ₹1036.20 | ₹1045.00 | ₹1030.00 | ₹1038.80 | 422.00 (Cr) | |
| ₹1040.00 | ₹1049.70 | ₹1027.30 | ₹1031.50 | 2.67K (Cr) | |
| ₹1056.50 | ₹1057.00 | ₹1032.10 | ₹1043.90 | 574.00 (Cr) |
Jenburkt Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1037.00 | ₹1057.00 | ₹960.30 | ₹992.00 | -4.34% | |
| ₹1087.95 | ₹1239.00 | ₹1010.00 | ₹1051.20 | -3.38% | |
| ₹1128.85 | ₹1136.00 | ₹1036.05 | ₹1076.90 | -4.60% | |
| ₹1152.00 | ₹1200.00 | ₹1100.10 | ₹1109.65 | -3.68% | |
| ₹1087.70 | ₹1245.00 | ₹1033.10 | ₹1151.20 | +5.84% | |
| ₹976.60 | ₹1070.00 | ₹961.00 | ₹1044.25 | +6.93% | |
| ₹997.00 | ₹1044.00 | ₹944.00 | ₹955.45 | -4.17% | |
| ₹1056.60 | ₹1099.95 | ₹981.00 | ₹1004.00 | -4.98% | |
| ₹1089.00 | ₹1168.90 | ₹1000.00 | ₹1073.40 | -1.43% | |
| ₹1175.00 | ₹1185.00 | ₹990.00 | ₹1089.80 | -7.25% | |
| ₹1299.00 | ₹1317.00 | ₹1140.00 | ₹1167.75 | -10.10% | |
| ₹1104.80 | ₹1321.00 | ₹991.20 | ₹1272.90 | +15.22% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Jenburkt Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Jenburkt Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of JENBURPH across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (20.40%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (27.15%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (24.18%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 12.85 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (61.01%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Excellent EPS Growth (18.85% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (17.92% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (110.72x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 3.00)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹48.26 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 0.12%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Jenburkt Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Jenburkt Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Jenburkt Pharmaceuticals LimitedJenburkt Pharma...Selected✓ JENBURPH • 524731 | 73.7/100 | ₹992.00₹992 | ₹483.43₹483.43 | 12.85Average 12.8 Average | 20.40%Excellent 20.40% Excellent | 27.15%Excellent 27.15% Excellent | 0.01Excellent 0.0 Excellent | 17.92%Excellent 17.92% Excellent | 9.08%Good 9.08% Good | 1.64% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1840.00₹1840 | ₹441471.20₹441471.20 | 36.51Average 36.5 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9322.00₹9322 | ₹247033.00₹247033.00 | 84.58Average 84.6 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4965.50₹4966 | ₹168062.31₹168062.31 | 79.32Average 79.3 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1119.10₹1119 | ₹111686.18₹111686.18 | 24.94Average 24.9 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1366.00₹1366 | ₹110352.31₹110352.31 | 32.73Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1969.00₹1969 | ₹106375.23₹106375.23 | 97.19Average 97.2 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1165.50₹1166 | ₹97319.25₹97319.25 | 30.12Average 30.1 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1679.80₹1680 | ₹96655.69₹96655.69 | 26.25Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2095.00₹2095 | ₹95793.88₹95793.88 | 17.31Average 17.3 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2280.00₹2280 | ₹94164.00₹94164.00 | 46.07Average 46.1 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price441471.20 Cr
- Divi's Laboratories Limited share price247033.00 Cr
- Torrent Pharmaceuticals Limited share price168062.31 Cr
- Zydus Lifesciences Limited share price111686.18 Cr
- Cipla Limited share price110352.31 Cr
Jenburkt Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for JENBURPH — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹58.86 | ₹1214.70 | 20.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Jenburkt Pharmaceuticals Limited Dividend History
Annual cash dividends paid by JENBURPH — dividend yield 1.64%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹6.78 Cr |
| FY 2024 | ₹6.32 Cr |
| FY 2023 | ₹5.50 Cr |
| FY 2022 | ₹4.68 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Jenburkt Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for JENBURPH — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
8.72%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
61.01%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.08%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
17.92%
Compounded annual net profit growth over 5 years
Jenburkt Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for JENBURPH — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Jenburkt Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Jenburkt Pharmaceuticals Limited (JENBURPH) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Jenburkt Pharmaceuticals Limited
About JENBURPH (Jenburkt Pharmaceuticals Limited)
Jenburkt Pharmaceuticals Ltd is a dynamic pharmaceutical company deeply rooted in the Indian healthcare landscape. With a legacy built on innovation and quality, Jenburkt is commit...ted to providing effective and accessible healthcare solutions to address prevalent health challenges. The company's diverse portfolio reflects a dedication to comprehensive patient care, encompassing a wide array of therapeutic segments. Jenburkt prides itself on a robust research and development program, constantly seeking to improve existing therapies and develop novel treatments that meet the evolving needs of the medical community and patients. The company’s core values are grounded in ethical business practices and a strong sense of social responsibility, fostering trust among healthcare professionals and consumers alike. Jenburkt's manufacturing processes adhere to stringent international quality standards, ensuring the safety and efficacy of its products. This dedication to quality is evident in its extensive range of offerings, which span critical therapeutic areas. From managing pain and inflammation to combating infections and metabolic disorders, Jenburkt aims to offer solutions for a broad spectrum of medical conditions. The company’s focus extends beyond prescription medications to include nutraceuticals and consumer healthcare products, reflecting a holistic approach to health and wellness. Driven by a passion for improving lives, Jenburkt continuously strives to expand its reach and impact, making a positive difference in the healthcare journey of individuals across India. Looking forward, Jenburkt Pharmaceuticals is poised for continued growth and innovation. The company is actively exploring new market opportunities and forging strategic partnerships to enhance its product offerings and expand its geographical presence. With a strong foundation built on research, quality, and a commitment to patient well-being, Jenburkt is well-positioned to contribute significantly to the advancement of healthcare in India. The company's leadership remains focused on fostering a culture of innovation and excellence, empowering its team to develop and deliver solutions that meet the evolving needs of the healthcare industry. As a trusted pharmaceutical provider, Jenburkt is dedicated to its mission of making quality healthcare accessible to all.
Company Details
Key Leadership
JENBURPH Share Price: Frequently Asked Questions
What is the current share price of Jenburkt Pharmaceuticals Limited?
Jenburkt Pharmaceuticals Limited (JENBURPH) trades at ₹992.00 on NSE and BSE. Market cap ₹483.43 (Cr). Educational data only.
What is the P/E ratio of Jenburkt Pharmaceuticals Limited?
Jenburkt Pharmaceuticals Limited has a P/E of 12.85x vs industry average 34.89x.
What is the Bull Run score for Jenburkt Pharmaceuticals Limited?
Jenburkt Pharmaceuticals Limited has a Bull Run score of 73.7/100 based on 25+ financial parameters.
Does Jenburkt Pharmaceuticals Limited pay dividends?
Jenburkt Pharmaceuticals Limited has a dividend yield of 1.64%. Past dividends don't guarantee future payments.
What is the ROE of Jenburkt Pharmaceuticals Limited?
Jenburkt Pharmaceuticals Limited has ROE of 20.40%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Jenburkt Pharmaceuticals Limited?
Jenburkt Pharmaceuticals Limited has debt-to-equity of 0.01.
Is Jenburkt Pharmaceuticals Limited a good investment?
Bull Run gives Jenburkt Pharmaceuticals Limited a score of 73.7/100. This is not investment advice — consult a SEBI-registered advisor.